Certara (NASDAQ:CERT - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $104.44 million for the quarter.
Certara Stock Performance
CERT stock traded down $0.30 on Friday, hitting $12.99. The company had a trading volume of 2,963,066 shares, compared to its average volume of 1,254,093. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 12-month low of $8.64 and a 12-month high of $17.81. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -64.95, a P/E/G ratio of 9.29 and a beta of 1.64. The stock's 50-day simple moving average is $11.70 and its 200 day simple moving average is $11.65.
Wall Street Analyst Weigh In
CERT has been the subject of several recent research reports. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Stephens reissued an "overweight" rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. KeyCorp raised their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Barclays lowered their target price on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Robert W. Baird upped their price target on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.
Check Out Our Latest Analysis on CERT
Certara Company Profile
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
